Clinical Trials Browser

Lymphoma, T-Cell, Peripheral

NCT04108325 2021-01-28

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Phase 1 Unknown

58 enrolled

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT03921879 2020-10-23

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Phase 1 Unknown

50 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT04008394 2019-08-07

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Phase 1 Unknown

50 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT00562068 2013-08-26

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

Phase 1 Unknown

30 enrolled

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma